Physician profile
Mark D Lee
NPI 1306144514
$972.10
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $222 · 2021: $63.61 · 2022: $51.91 · 2023: $67.43 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $260.97 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $179.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $115.38 | 2019-2024 | Vaxneuvance, Gardasil, Vaqta |
| Gilead Sciences, INC. | $111.20 | 2020-2024 | Descovy |
| Organon LLC | $60.21 | 2024 | |
| Glaxosmithkline, LLC. | $43.94 | 2019-2023 | Arexvy |
| Novo Nordisk INC | $36.02 | 2019 | |
| Allergan, INC. | $30.03 | 2019-2020 | |
| Boston Scientific Corporation | $24.61 | 2022 | |
| Daiichi Sankyo INC. | $24.22 | 2019 | |
| Dynavax Technologies Corporation | $23.30 | 2023 | Heplisav-B |
| Genentech USA, INC. | $16.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.70 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $15.38 | 2019 | |
| Astellas Pharma US INC | $14.98 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.